enVVeno Medical Corp financial data

Symbol
NVNO on Nasdaq, NVNBW on OTC
Industry
Surgical & Medical Instruments & Apparatus
Location
70 Doppler, Irvine, CA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Hancock Jaffe Laboratories, Inc. (to 9/22/2021)
Latest financial report
10-Q - Q2 2024 - Jul 31, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.37K % -0.74%
Debt-to-equity 7.01 % -11.8%
Return On Equity -54.2 % +22.2%
Return On Assets -50.7 % +21.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 13.3M shares +40.7%
Common Stock, Shares, Outstanding 13.3M shares +40.7%
Entity Public Float 29.2M USD -18.4%
Weighted Average Number of Shares Outstanding, Basic 16.1M shares +43.1%
Weighted Average Number of Shares Outstanding, Diluted 16.1M shares +43.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 11.7M USD -11%
Operating Income (Loss) -22.6M USD +13.9%
Nonoperating Income (Expense) 1.99M USD +84.1%
Net Income (Loss) Attributable to Parent -20.6M USD +18.1%
Earnings Per Share, Basic -1.38 USD/shares +38.7%
Earnings Per Share, Diluted -1.38 USD/shares +46.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.38M USD -49.5%
Assets, Current 39.5M USD +31.3%
Property, Plant and Equipment, Net 252K USD -42.5%
Operating Lease, Right-of-Use Asset 1.18M USD -22.1%
Assets 41M USD +27.8%
Accounts Payable, Current 1.7M USD +239%
Liabilities, Current 1.7M USD -18%
Operating Lease, Liability, Noncurrent 882K USD -26.9%
Liabilities 2.58M USD -21.3%
Retained Earnings (Accumulated Deficit) -140M USD -17.3%
Stockholders' Equity Attributable to Parent 38.4M USD +33.3%
Liabilities and Equity 41M USD +27.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.55M USD +30.5%
Net Cash Provided by (Used in) Financing Activities 46K USD
Net Cash Provided by (Used in) Investing Activities 2.2M USD -22.3%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 13.3M shares +40.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.31M USD +42.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 45K USD +800%
Deferred Tax Assets, Gross 25.4M USD +27.9%
Operating Lease, Liability 1.4M USD -18.3%
Depreciation 100K USD 0%
Payments to Acquire Property, Plant, and Equipment 10K USD +100%
Lessee, Operating Lease, Liability, to be Paid 1.51M USD -19.9%
Property, Plant and Equipment, Gross 1.41M USD +2.76%
Operating Lease, Liability, Current 351K USD -0.28%
Lessee, Operating Lease, Liability, to be Paid, Year Two 399K USD +3.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 387K USD +2.93%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 110K USD -36%
Lessee, Operating Lease, Liability, to be Paid, Year Three 411K USD +3.01%
Deferred Tax Assets, Operating Loss Carryforwards 17.2M USD +16.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 315K USD -23.4%
Additional Paid in Capital 178M USD +20.4%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 24.9M USD +28.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%